StreetAlpha
13F holdings · Q3 2026

Samsara Biocapital

Palo Alto, CA · files as Samsara Biocapital, LLC
Know the moment Samsara Biocapital filesYou follow Samsara Biocapital An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1744967

Samsara Biocapital reported 27 stocks worth $1.1B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are SRRK (31.7%), MLYS (14.0%) and SEPN (11.4%). Compared with Q2 2026, the fund opened new positions in PMVP, OBX and TCGX, added to ALMS, NGNE and VTVT, trimmed SEPN, AQST and AGMB and sold out of GOSS.

Latest filing: what Samsara Biocapital did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
4 new3 added6 trimmed1 sold outBought about $38.4M · sold about $5.3M
New 4
Added 3
Trimmed 6
See all 6 →
Sold out 1

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$1.1B−13.6% vs last quarter
Stocks held274 new · 1 sold out
Top 5 weight70.4%very concentrated
Turnover4%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
SRRK
Scholar Rock Hldg Corp
$333M31.7%6.9MNo change8 of 8
2
MLYS
Mineralys Therapeutics Inc
$148M14.0%5.9MNo change8 of 8
3
SEPN
Septerna Inc
$120M11.4%3.1M−83K (−3%)8 of 8
4
ALMR
Alamar Biosciences Inc
$84.5M8.0%2.5MNo change2 of 8
5
SGP
Spyglass Pharma Inc
$54.9M5.2%2.1MNo change3 of 8
6
ALMS
Alumis Inc
$53.5M5.1%7.2M+891K (+14%)8 of 8
7
NGNE
Neurogene Inc
$51.9M4.9%1.9M+150K (+9%)8 of 8
8
KLRS
Kalaris Therapeutics Inc
$37.2M3.5%12.9MNo change7 of 8
9
IVA
Inventiva SA
$23.3M2.2%6.3MNo change4 of 8
10
PBLS
Parabilis Medicines Inc Com
$18M1.7%556KNo change2 of 8
🔒 17 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
GOSS
Gossamer Bio Inc
$1.2M7.2M

Reported value

last 8 quarters
$729MQ4 '24
$561MQ1 '25
$489MQ2 '25
$766MQ3 '25
$969MQ4 '25
$1BQ1 '26
$1.2BQ2 '26
$1.1BQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Samsara Biocapital 13F FAQ

What does Samsara Biocapital own?

Samsara Biocapital reported 27 stocks worth $1.1B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are SRRK (31.7%), MLYS (14.0%) and SEPN (11.4%). The table above lists every position in the filing (the top 10 without an account).

What did Samsara Biocapital buy and sell in Q3 2026?

Compared with Q2 2026: 4 new positions, 3 added to, 6 trimmed and 1 sold out. New positions include PMVP, OBX and TCGX. It sold all of GOSS.

When will Samsara Biocapital file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Samsara Biocapital's portfolio worth?

The Q3 2026 filing reports $1.1B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.